The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | The potential of early intervention for high-risk patients with Waldenström’s macroglobulinemia
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the potential of early intervention in high-risk Waldenström’s macroglobulinemia, drawing lessons from multiple myeloma. He emphasizes that with more effective therapies available, studies are being considered to determine if early intervention could improve patient outcomes. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie, Adaptive, Amgen, BMS, GSK, J&J, Legend, Novartis, OncoPep, Pfizer, Takeda, Sebia, Recordati.
